Evidence map›Paper›PMID 40450298›Full record

SynthesisOrphanet journal of rare diseases2025

Understanding the clinical morbidity and mortality of fibrodysplasia ossificans progressiva: a systematic literature review.

Hind Harrak, Susan Rhee, Amal Souttou, Sarah J O'Meara, Caitlin Knox

Abstract readSystematic Review
In one paragraph

Synthesis in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hind HarrakRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Susan RheeRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Amal SouttouRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Sarah J O'MearaRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Caitlin KnoxRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. caitlin.knox@regeneron.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFibrodysplasia ossificans progressiva (FOP) is an autosomal dominant ultra-rare disease characterized by progressive episodic multi-focal heterotopic ossification of skeletal muscle, ligaments, tendons, and fascia. Comprehensive characterization and understanding of the natural disease history of FOP, including mortality, comorbidities, and medication use, is currently limited.

objectiveThis systematic review, which we believe is the first of its kind, aims to synthesize current knowledge on the morbidity, mortality, and medication use associated with FOP.

methodsA systematic literature review (SLR) was conducted utilizing various databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials, the Trip database, and National Institute for Health and Care Excellence documents. The search was limited to studies involving humans, but was not restricted based on language. The studies used reported at least one of the following outcomes: mortality, comorbidity, and medication use; any clinical trials that were solely designed to evaluate a symptomatic treatment for FOP, such as flare-ups and pain, were excluded. Two independent reviewers reviewed and selected the included studies of the review, and extraction was done by one reviewer with cross-check performed by the other person. The Joanna Briggs Institute Critical Appraisal Checklist, specifically designed for studies reporting prevalence data, was used to assess the quality of studies. The SLR was registered on Prospero (CRD42022366914).

resultsIn total, 32 publications were selected for review. These studies included a wide range of participants age (0.1-78 years), study duration (1 day-33 years), and sample size (3-299 patients). Ten studies reported information on mortality, 26 studies reported on comorbidities, and 12 reported information on medication use. The three organ systems most affected by the conditions studied were, in order of severity, the cardiovascular (40-70%), skeletal (50-65%), and respiratory (20-42%).

conclusionsAlthough FOP is an ultra-rare disease, the available literature demonstrates that it is associated with excess morbidity and mortality. Our review synthesized all available published estimates of epidemiologic landscape of FOP and demonstrates the need for future work to better understand this rare disease.

Indexed as

Myositis OssificansHumansMorbidityComorbidityEpidemiologyFibrodysplasia ossificans progressivaMedication useMortalitySystematic literature review

Identifiers

PMID40450298
PMCPMC12125817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.